Showing results (21-30 of 3,350) with videos related to

Sort By:
Pageof 335
The Lancet. Oncology|May 18, 2010
Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies, Timothy J Key, Paul N Appleby, et al.
The Lancet. Oncology|September 25, 2010
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trialPeter Gimsing, Kristina Carlson, Ingemar Turesson, et al.
The Lancet. Oncology|September 25, 2010
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trialAxel Le Cesne, Isabelle Ray-Coquard, Binh Nguyen Bui, et al.
The Lancet. Oncology|June 29, 2010
Treatment non-adherence in teenage and young adult patients with cancerHelena J Kondryn, Claire L Edmondson, Jonathan Hill, et al.
The Lancet. Oncology|January 18, 2011
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialChristopher M Nutting, James P Morden, Kevin J Harrington, et al.
The Lancet. Oncology|October 19, 2010
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studySilvia de Sanjose, Wim Gv Quint, Laia Alemany, et al.
The Lancet. Oncology|June 12, 2010
Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer riskMichael R Speicher, Jochen B Geigl, Ian P Tomlinson
The Lancet. Oncology|December 21, 2010
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 studyUlrich Gatzemeier, Joachim von Pawel, Ihor Vynnychenko, et al.
The Lancet. Oncology|November 27, 2010
Oesophagogastric junction adenocarcinoma: which therapeutic approach?Christophe Mariette, Guillaume Piessen, Nicolas Briez, et al.
The Lancet. Oncology|August 27, 2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trialMaría-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Pageof 335